Achieve Life Sciences, INC 10-Q quarterly reports

Achieve Life Sciences reported its first quarter 2026 financial results, highlighting a net loss of $10.2 million and a significant capital raise of $180 million, while also anticipating a delay in FDA approval for cytisinicline.

Achieve Life Sciences reports Q3 2025 results, highlighting FDA acceptance of its cytisinicline NDA for smoking cessation and a national priority voucher for vaping cessation, amidst ongoing financing needs and a supplier dispute.

Achieve Life Sciences submitted its New Drug Application for cytisinicline for smoking cessation and secured significant funding, extending its cash runway into late 2026.

Achieve Life Sciences reports a net loss of $12.8 million for Q1 2025 while advancing cytisinicline towards NDA submission and Phase 3 vaping cessation trials.

Achieve Life Sciences' Q3 2024 report details financial results and progress in clinical trials for cytisinicline, including the completion of enrollment for the ORCA-OL safety trial.

Achieve Life Sciences reports a net loss of $15.0 million for the first half of 2024, while advancing its cytisinicline program towards potential FDA approval.

Achieve Life Sciences reported a net loss of $6.5 million for Q1 2024, while also securing $56.1 million in net proceeds from a private placement to advance the development of cytisinicline.